Recent Updates — DGX
On October 21, 2026, Quest Diagnostics learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and view results. The company initiated cybersecurity response procedures, notified federal law enforcement, and engaged external experts to investigate the scope of the breach. Management believes an unauthorized party accessed certain patient records but stated that operations have not been materially disrupted. Quest Diagnostics operates in the clinical laboratory testing industry.
Quest Diagnostics reported third-quarter net revenues of $3.10 billion, a 10% increase from the prior year, driven by strong organic growth across physician, hospital, and consumer channels. Reported diluted earnings per share reached $2.78, up 28.7%, while adjusted diluted EPS was $3.00, reflecting a 15.4% gain. The company raised its full-year 2026 revenue guidance to between $12.065 billion and $12.105 billion and increased its adjusted diluted EPS outlook to between $11.25 and $11.35, citing productivity gains from automation and AI as well as expanding clinical care needs for an aging population. Quest Diagnostics is a leading provider of diagnostic information services.
Quest Diagnostics announced that Catherine T. Doherty will transition to Executive Vice President effective November 1, 2026, overseeing health systems, the joint venture with Corewell Health, and Project Nova. She is scheduled to retire in July 2027. The company approved a $1.2 million restricted stock unit award for her new role, while maintaining her $650,000 base salary and 80% target incentive compensation. Quest Diagnostics operates as a leading diagnostic information services company.
Quest Diagnostics reported second quarter 2026 revenues of $3.04 billion, a 10.2% increase from 2025, and adjusted diluted EPS of $3.12, up 19.1% year-over-year. The company raised its full year 2026 guidance, now expecting revenues between $11.95 billion and $12.05 billion and adjusted diluted EPS between $11.05 and $11.25. Quest Diagnostics is a provider of diagnostic information services.
Quest Diagnostics announced the results of its 2026 Annual Meeting, where stockholders elected all director nominees and approved executive compensation and the appointment of PricewaterhouseCoopers. A stockholder proposal to mandate an independent board chairman was defeated, receiving 23,999,636 votes in favor and 69,792,819 votes against.
Quest Diagnostics Incorporated issued $500 million in aggregate principal amount of 5.000% senior notes due 2036. The notes are senior unsecured obligations of the company and are scheduled to mature on June 30, 2036.